Analytical Data
-
Gene name
mxiH
- Application
-
Alternative Names
mxiH; CP0137; Protein MxiH
-
Species
Shigella flexneri
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P0A223
-
Expression Region
1-83aa
-
Molecular Weight
16.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The mxiH gene, a pivotal component within the type III secretion system (T3SS) of pathogenic bacteria, has garnered significant attention in microbiological research due to its role in virulence and host-pathogen interactions. This gene encodes a protein that is essential for the translocation of effector proteins into host cells, enabling the bacteria to manipulate host cellular processes for their survival and proliferation. Given its integral function in disease progression, particularly in enteropathogenic bacteria such as *Shigella* and *Salmonella*, the recombinant mxiH protein has become a target for studying the mechanisms of bacterial infection and immune evasion. Researchers are increasingly focused on characterizing the structure and functionality of this protein to identify potential therapeutic targets and develop novel intervention strategies. The study of mxiH is not only crucial for understanding bacterial pathogenesis but also holds promise for vaccine development and enhancing our knowledge of host immunity against bacterial infections. Insights from mxiH research could lead to improved diagnostics, treatments, and preventive measures against diseases caused by these pathogens, thereby addressing a significant public health challenge.
